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ABSTRACT
Aim To co- produce with young people an educational 
package about the human papillomavirus (HPV) vaccine 
that is tailored to increase vaccine uptake in schools and 
populations with lower uptake.
Introduction Persistent infection with HPV can result 
in cancers affecting men and especially women. From 
September 2019, the English- schools- based HPV 
vaccination programme was expanded to include young 
men (in addition to young women) aged 12–13 years. 
Some young people attending schools with lower uptake 
of the vaccine have unmet information needs. We 
hypothesise that mechanisms to address information 
needs and increase young people’s autonomy in consent 
procedures will result in higher uptake.
Methods and analysis The Medical Research Council’s 
framework for development and evaluation of complex 
interventions will inform intervention development. 
Recruitment of young people aged 12–15 years and key 
stakeholders (National Health Service commissioners, 
school staff, immunisation nurses and youth workers/
practitioners) will be facilitated through existing links 
with healthcare organisations, schools and youth 
organisations in areas with lower uptake of the HPV 
vaccination programme. The proposed research will 
comprise three phases: (1) a rapid review of adolescent 
immunisation materials and preliminary qualitative 
interviews with young people and key stakeholders, (2) 
theory development and co- production of HPV vaccine 
communication materials through an iterative process 
with young people and (iii) testing delivery mechanisms 
and acceptability of the educational package in four 
schools with lower uptake.
Ethics and dissemination The University of Bristol’s 
Faculty of Health Sciences and London School of Hygiene 
and Tropical Medicine's Research Ethics Committees 
provided approvals for the study. A dissemination event 
for young people and key stakeholders and webinar with 
the National Immunisation Network will be organised. The 
study findings will be published in peer- reviewed journals 
and presented at conferences. Recommendations for a 
future larger scale study will be made.
INTRODUCTION
The human papillomavirus (HPV) vaccine 
currently used in England protects against 
infection from high- risk HPV types 16 and 
18, which cause cancers affecting the cervix, 
vulva, vagina, penis, anus and oral cavity. 
The vaccine also protects against types 6 and 
11, which cause 90% of genital warts. High 
coverage of the English HPV vaccination 
programme for young women aged 12–13 
years has been achieved. Recent evidence 
for population- level effectiveness has high-
lighted the potential for HPV vaccination 
programmes to eradicate cervical cancer.1 2
However, national data often conceal 
within- country inequalities in uptake and 
access. Without concerted efforts to address 
Strengths and limitations of this study
 ► This study aims to co- produce with young people an 
educational package that addresses young people’s 
information needs about the human papillomavirus 
vaccination programme.
 ► The protocol for this study documents the use of an 
innovative, participatory methodological approach.
 ► Communication materials will be iteratively de-
signed by the co- production team, taking into 
account young people’s views at all stages of the 
development cycle.
 ► Findings from this study will be used to make rec-
ommendations for a future larger scale study.
 ► Parents, who also have unmet information needs, 
are not included in this study.
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lower uptake among some populations, existing dispari-
ties in the incidence of cervical cancer by ethnicity and 
socioeconomic deprivation may increase.3–5 Wide vari-
ations in uptake of the HPV vaccination programme 
across local authorities exist (range: 70.2%–95.8% for the 
first dose in 2018/2019).6 We previously identified lower 
uptake by area and among some population groups, 
including minority ethnic groups.7 Our research in 
schools with lower uptake showed complex sociocultural 
factors influence beliefs and priorities for young women 
to be vaccinated.8 The requirement for written parental 
consent also acts as a major barrier,9 which can be over-
come to some extent by enabling verbal parental consent 
and adolescent self- consent.10 11
Based on emerging evidence, the Joint Committee 
on Vaccination and Immunisation concluded that 
extending the HPV vaccination programme to include 
young men could be cost effective.12 The Department 
of Health announced the inclusion of young men from 
the 2019/2020 programme year. If sufficient uptake 
is attained, a universal vaccination programme will 
strengthen England’s position to eliminate some HPV 
types and HPV- related cancers in the longer term. Men 
who have sex with men will also receive optimal protec-
tion by immunisation ahead of sexual debut.12 13
It is currently unknown whether the universal HPV 
vaccination programme will be delivered equitably by 
gender, or whether existing inequalities in uptake and 
incidence of HPV- related disease among some groups 
will be decreased or widened.14 Inequalities may prevent 
delivery of the programme as intended, with insufficient 
understanding and engagement of young people and 
their parents or carers.
Despite largely positive public attitudes to vaccination,15 
recent calls have been made to tackle negative miscon-
ceptions of vaccines and limit health misinformation 
circulating in social media.16 Many young people have 
limited or no understanding of the vaccines they receive 
or the diseases they are intended to prevent.17
Our previous research confirms some young women 
attending schools with lower uptake have unmet infor-
mation needs, which can have implications for obtaining 
consent and vaccination uptake8 (H Fisher et al, 2020, 
unpublished data). A systematic review, including two 
UK- based studies, showed young men have lower knowl-
edge and understanding of HPV than their female 
counterparts.18
Methods to increase understanding, suggested by fami-
lies and professionals, include: healthcare professional 
advocacy, accessible information formats, and delivery of 
educational sessions, in addition to the routine provision 
of information leaflets (H Fisher et al, 2020, unpublished 
data). Preliminary feedback from young people suggests 
the delivery of interactive HPV vaccine awareness raising 
sessions by a researcher in the school setting are accept-
able. Young people’s questions during the sessions related 
both to the HPV vaccine and preparation for the vaccina-
tion session.
A systematic review suggested weak evidence for the 
effectiveness of educational interventions at increasing 
acceptance, or intentions for their daughter to receive the 
HPV vaccine.19 However, the review requires updating as 
the primary studies were predominantly related to hypo-
thetical scenarios prior to vaccine licensing, and more 
studies have since been published.
Internationally, educational interventions about the 
HPV vaccine have been developed through research. 
These have targeted young adults,20 21 parents22–24 and 
professionals.22–24 A complex intervention delivered in 
a USA’s healthcare setting, comprising an educational 
component delivered by healthcare providers to young 
people aged 11–21 years, was shown to be effective at 
increasing uptake.25 Similarly, a schools- based educa-
tional programme delivered through 113 face- to- face 
classes with Swedish students aged 16 years was shown 
to increase self- reported uptake of the HPV vaccine.26 In 
Australia, a complex, schools- based intervention was not 
shown to be effective at increasing vaccination uptake, 
but improved adolescent knowledge and psychosocial 
outcomes.27
These studies suggest that an educational- based 
intervention to increase uptake has potential to be an 
acceptable and effective intervention in the context of 
the English universal HPV vaccination programme. We 
hypothesise that mechanisms to address information 
needs and increase young people’s autonomy in consent 
procedures will result in higher uptake of the programme. 
We are unaware of any other educational packages that 
have been developed specifically for areas and popula-
tions groups with lower uptake,7 or that have tested these 
specific mechanisms to increase uptake.
The aim of the study is to co- produce jointly with young 
people an HPV vaccination educational package that can 
be used within the adolescent schools- based immuni-
sation programme and is tailored at increasing vaccine 
uptake in areas and populations with lower HPV vaccina-
tion coverage.
METHODS AND ANALYSIS
We propose an innovative, participatory research approach 
involving co- production of an education package about 
the HPV vaccine with young people. The 2008 Medical 
Research Council's guidance for complex intervention 
development and evaluation will be followed.28
Patient and public involvement
The design of this study was informed by our qualitative 
research undertaken with young women, parents, immu-
nisation nurses and school staff29 (H Fisher et al, 2020, 
unpublished data). We have consulted with the Bristol 
Young People’s Advisory Group (YPAG) and Bristol City 
Youth Council about the design of the study. The Bristol 
YPAG comprises young people aged 10–17 years who are 
interested in healthcare and research. The Bristol City 
Youth Council is an elected group of 28 young people 
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from across the city. Both groups have been consulted 
about the design of the study and participant materials. 
They will also be invited to an event at the end of the 
study to consider findings and recommendations with the 
young people, healthcare professionals and school staff 
involved in the study.
The study will comprise three phases: (1) a rapid review 
of adolescent immunisation information materials and 
preliminary qualitative interviews with young people and 
key stakeholders, (2) theory development and co- pro-
duction of HPV vaccine communication materials in an 
iterative process with young people and (3) examining 
delivery mechanisms and acceptability of the educational 
package in four schools with lower uptake of the HPV 
vaccination programme.
Recruitment
During stages one and two, young men and women aged 
12–15 years will be recruited from two youth community 
organisations in the south west of England. These organ-
isations work with young people with similar sociodemo-
graphic backgrounds to the participants of our previous 
studies undertaken in schools with lower uptake. An addi-
tional youth community organisation in London has also 
been recruited. The age group 12–15 years is selected, 
as these young people will have diverse experiences in 
relation to the HPV vaccination programme. Key stake-
holders will initially be identified through the research 
teams’ existing relationships with youth organisations, 
immunisation teams and schools in the study areas. Addi-
tional interviews may be undertaken if other key individ-
uals are identified as the activities progress.
Stage one
A scoping review of existing young people’s immunisa-
tion information materials will be undertaken. Web- based 
searches will be undertaken to locate online HPV vaccine 
communication tools targeted at young people in English- 
speaking countries. A description of the characteristics, 
format and content of the communication tools will be 
provided. The findings will be used to make recommen-
dations to inform the content of the initial workshop.
Our qualitative research findings suggest that young 
people value external providers delivering health- related 
information in school settings. Preliminary individual or 
paired/peer group interviews (depending on the prefer-
ence of participants) with young people (n~6) and key 
stakeholders (commissioners, school staff, immunisation 
nurses and youth workers/practitioners) (n~6) will be 
undertaken to explore further who should deliver the 
educational package and which key messages to cover.
Stage two
Drawing on our previous qualitative research findings, 
it is envisaged that the educational package will include 
question and answer sessions alongside a series of short 
videos. Information needs may differ between schools 
depending on the sociodemographic characteristics of 
the student population. Therefore, additional videos 
will be co- produced to allow the educational session to 
be tailored as appropriate (eg, provision of information 
in multiple languages and additional information for 
parents on vaccine safety).
The materials will be co- produced by young people 
(n~6) and creative designers who are experienced in 
working with young people to create health- related media 
materials.
An initial workshop with young people (n~6–8) will be 
organised at a community youth organisation where they 
will be asked to (1) review existing communication mate-
rials; (2) comment on their understanding of key HPV 
vaccine messages; (3) make suggestions of their preferred 
messages, design and language style and (4) propose the 
type of media to be used (eg, animation and vloggers). 
Platforms to distribute the communication materials (eg, 
videos and powerpoints), which are accessible by young 
people, will be explored. Advice will also be sought from 
voluntary organisations, immunisation teams and school 
staff.
At least three additional workshops will be organised 
in different community youth organisations. Here, the 
materials will be iteratively redesigned by the co- produc-
tion team. Young people’s views will be taken into account 
at all stages of the development cycle.
Stage three
Four schools with lower uptake of the HPV vaccination 
programme will be recruited to the study. Identification 
of potential schools to approach will be made in collab-
oration with the local immunisation teams in Bristol and 
London and our existing relationships with schools. It is 
envisaged that the educational package will last approx-
imately 1 hour and be delivered to groups of vaccine 
eligible young people (aged 12–13 years). The package 
will be piloted approximately 2 weeks ahead of the sched-
uled vaccination session. Methods for obtaining young 
people’s feedback will be explored (eg, short paper- based 
questionnaires and interactive quiz). Following the ques-
tion and answer session, young people will be provided 
with consent forms and promotional materials available 
in different languages. Young people will be encouraged 
to share these with their parents/carers and return the 
completed consent form.
The feasibility of obtaining information from immuni-
sation teams relating to HPV vaccine uptake by gender, 
ethnicity, deprivation and types of consent routinely 
obtained (no response, parent refusal, written or verbal 
parental consent, young person refusal or self- consent) 
will be assessed in terms of timeliness of data acquisition 
and levels of completeness for a future study.
A purposive sample of young people (n~12) from 
participating schools and key stakeholders (n~12) will 
be invited to take part in semi- structured or paired/
peer group interviews (depending on the preference of 
participants) to gather information related to interven-
tion acceptability, understanding of the HPV vaccine, 
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and perceptions of adolescent autonomy during consent. 
Potential key stakeholders to invite to interview will be 
identified by the research team as the research activities 
progress. The feasibility and sustainability of who delivers 
the education package will be further explored.
Analysis
All interview recordings will be transcribed verbatim and 
any potentially identifying information removed. Familia-
risation with the data will involve two researchers reading 
and discussing the transcripts to compare and begin to 
code and categorise the data. Thematic analysis30 will be 
undertaken, within which similarities and differences 
will be explored. Data analysis will be assisted by the QSR 
NVivo V.12 software package.
Together, the findings from the rapid review and qual-
itative research will inform the logic model and develop-
ment of theory for the educational package.
The outcome from this participatory research study 
will be a tailored educational intervention about the 
universal HPV vaccination programme. We will seek addi-
tional funding to test whether the educational package 
can: (1) improve uptake of the vaccination programme 
in schools/areas with lower uptake; (2) reduce inequali-
ties in programme delivery; (3) increase young people’s 
understanding about the HPV vaccine and (4) increase 
young people’s autonomy in decision- making and consent 
procedures. For this larger scale study, we plan to design 
an intervention based on behaviour change theory (eg, 
COM- B model) which uses delivery of the educational 
materials we will have co- produced alongside other strat-
egies to support behaviour change.
ETHICS AND DISSEMINATION
In March 2020, the University of Bristol’s Faculty of Health 
Sciences and London School of Hygiene and Tropical 
Medicine's Research Ethics Committees provided ethical 
approvals for the study (references: 99102 & 21887). The 
project began recruitment and data collection in April 
2020 and the study's activities will finish in March 2021.
We will disseminate this research to the academic 
community, health and youth work practitioners and 
health policy workers. For the academic community, we 
plan to submit at least one peer- reviewed paper. We will 
also disseminate the results to at least one national and 
one international conference. For practitioners, we will 
complete a report of our findings and will disseminate 
the results through practitioner conferences and events.
We will also hold a community stakeholder event to 
which we will invite school nurses, school staff, parents 
and young people. This will be an opportunity to discuss 
the educational package for the HPV vaccine. Healthcare 
professionals will be actively encouraged to be involved in 
the dissemination activities, and findings from the study 
will also be disseminated through appropriate websites 
and social media. The final report of the study will also 
provide an opportunity for further dissemination.
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